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Melanomas driven by loss of the NF1 tumor suppressor have a high risk of treatment failure and 24 
effective therapies have not been developed.  Here we show that loss-of-function mutations of nf1 25 
and pten result in aggressive melanomas in zebrafish, representing the first animal model of NF1-26 
mutant melanomas harboring PTEN loss.  MEK or PI3K inhibitors show little activity when given 27 
alone due to cross-talk between the pathways, and high toxicity when given together.  The mTOR 28 
inhibitors, sirolimus, everolimus and temsirolimus, were the most active single agents tested, 29 
potently induced tumor-suppressive autophagy, but not apoptosis.  Because addition of the BCL2 30 
inhibitor venetoclax resulted in compensatory upregulation of MCL1, we established a three-drug 31 
combination composed of sirolimus, venetoclax and the MCL1 inhibitor S63845.  This well-32 
tolerated drug combination potently and synergistically induces apoptosis in both zebrafish and 33 
human NF1/PTEN-deficient melanoma cells, providing preclinical evidence justifying an early-34 





Cutaneous melanoma accounts for the vast majority of skin cancer-related deaths. More than 38 
100,000 newly diagnosed cases of melanoma are projected in the United States for 2020 together 39 
with ∼6,800 melanoma-related deaths1. The Cancer Genome Atlas (TCGA) classified cutaneous 40 
melanomas into four molecular subtypes: BRAF-mutant (47.5%), RAS-mutant (29%), NF1-mutant 41 
(9%), and triple-wild-type (14.5%)2. The NF1-mutant category refers to cases lacking either 42 
BRAF or RAS mutations, whereas NF1 mutations can also arise as a mechanism of resistance to 43 
RAF/MEK-targeted therapies in BRAF-mutated melanoma3,4.  Thus, NF1 mutations have been 44 
reported in 13-17% of cutaneous melanomas overall2,5,6.  45 
The NF1 gene encodes neurofibromin, a 2818-amino-acid protein whose GTPase-activating 46 
protein-related domain negatively regulates RAS signaling by catalyzing the hydrolysis of RAS-47 
GTP into RAS-GDP. Thus, one consequence of NF1-loss is the aberrant activation of RAS 48 
signaling7.  In primary melanoma patient biopsies, NF1 mutations were not correlated with hot-49 
spot BRAF mutations, a finding consistent with a redundant role for these two types of mutations 50 
in activating RAS-MAPK signaling.  51 
 Recent efforts to develop improved targeted therapies for melanoma have mainly focused 52 
on the BRAF-mutant subtype, leaving a paucity of treatment options for patients with NF1-mutant 53 
melanomas. It is unlikely that the FDA-approved BRAF-mutant-specific inhibitors will be 54 
beneficial against BRAF-wild-type, NF1-mutant melanomas. Moreover, analysis of multiple 55 
clinical trials indicate that the NF1-mutant subtype has the worst outcome among all metastatic 56 
melanomas8. Clearly, a better understanding of the molecular pathogenesis of NF1-mutant 57 
melanomas is needed to improve the design and hence the outcome of treatments for this subtype 58 
of melanoma. 59 
A major impediment to the development of targeted therapies for patients with NF1-mutant 60 
melanomas has been the lack of suitable animal models. For example, both the BRAF-mutant and 61 
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RAS-mutant subtypes of melanoma have been successfully modeled in mice9 and zebrafish10 by 62 
combining the melanoma-associated mutations in these genes with mutation or loss of p53 or 63 
Cdkn2a, which are both typically inactivated in human melanoma2,11. However, Nf1-loss was not 64 
sufficient to induce melanoma tumorigenesis in mice3,12 or zebrafish13, either alone or in 65 
combination with p53-loss.  As the NF1-mutant melanomas often harbor a high mutation load14,15, 66 
we reasoned that genetic or epigenetic alterations affecting genes other than p53 and Cdkn2a are 67 
likely required in combination with NF1-loss to initiate melanoma transformation in vivo.  68 
Because a significant subset of human NF1-mutant melanomas harbor genetic alterations leading 69 
to activation of the PI3K-AKT-mTOR pathway2,6, we hypothesized that targeting this pathway 70 




Results  73 
 74 
Loss-of-function mutations of nf1 and pten cooperate to drive melanomagenesis in p53-75 
deficient zebrafish. 76 
 We previously reported the development of nf1a+/-;nf1b-/- zebrafish lines with loss of three 77 
of the four functional alleles of nf113. These animals develop spontaneous malignant peripheral 78 
nerve sheath tumors (MPNSTs) with low penetrance, but not melanomas, beginning at the age of 79 
1.5 years, indicating that nf1-loss alone is not sufficient to drive melanomagenesis 80 
(Supplementary Figure S1). When we bred the nf1a+/-;nf1b-/- line into a p53-deficient 81 
(p53M214K/M214K) background, the compound mutant fish developed MPNSTs or high-grade 82 
gliomas13.  Although rare spontaneous melanomas were also detected, they had a very low 83 
penetrance (<2%) over the course of 40 weeks (Supplementary Figure S1). Because human NF1-84 
mutant melanomas often harbor gain-of-function alterations in the PI3K signaling pathway, 85 
including mutational inactivation of PTEN or overexpression of AKT32,6, we introduced pten 86 
loss-of-function mutations into nf1a+/-;nf1b-/-;p53M214K/M214K zebrafish by crossing with a 87 
previously established ptena+/-;ptenb-/- line16,17. We then incrossed nf1a+/-;nf1b+/-;ptena+/-;ptenb+/-88 
;p53+/M214K fish and monitored the offspring for spontaneous tumor development every 2 weeks 89 
starting at 5 weeks of age. Very aggressive melanotic tumors began to appear in these fish at 7 90 
weeks of age, with a penetrance of 80% by 20 weeks (Figures 1a-e).  Histopathologic study of the 91 
melanotic tumors revealed a dense, cellular neoplasm in which a subset of the neoplastic cells 92 
produced pigment, with an overall histology pathognomonic of malignant melanoma (Figures 1b-93 
d).  Thus, activation of the PI3K pathway appears to be a critical requirement for melanomas to 94 
develop, in this case in concert with loss of NF1 and p53.  95 
Melanomas arising in the nf1/pten/p53-mutant background were highly invasive into 96 
underlying musculature (Figures 1b-d), and developed much earlier than melanomas in either the 97 
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Tg(mitf:BRAFV600E);p53M214K/M214K or Tg(mitf:NRASQ61K);p53M214K/M214K zebrafish18-21.  MPNSTs 98 
and glioblastomas appear in the nf1/p53 background after 30 weeks of age, while melanomas 99 
develop starting at 5 weeks of age in the nf1/pten/p53 background and grow so rapidly that fish 100 
usually need to be sacrificed for humane reasons before 30 weeks of age, so melanomas are the 101 
only tumor-type observed in the nf1/pten/p53 background.  Importantly, these spontaneous 102 
melanomas arose exclusively in fish that were homozygous null for both nf1b and ptenb, 103 
heterozygous for nf1a and ptena mutant alleles, and either heterozygous or homozygous for 104 
p53M214K (Figures 1 and S2).  DNA PCR from melanoma tumors and adjacent normal tissue 105 
showed that the wild-type allele of nf1a and ptena is retained by the tumor cells (Supplementary 106 
Figure S3). The nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-;p53M214K/M214K tumors (designated “nf1/pten-107 
mutant melanomas”) developed at random sites across the surface of the fish (Figure 1a). The 108 
pigmented melanoma cells were highly invasive, infiltrating skeletal muscle adjacent to every 109 
tumor examined for histology (Figures 1b-d).  Hence, retention of only one allele of both nf1 and 110 
pten in a p53-mutant background drives the development of highly invasive malignant melanoma 111 
in our zebrafish model.   112 
 113 
The nf1/pten-mutant melanomas lack braf/nras hot-spot mutations. 114 
 Since 80% of human cutaneous melanomas harbor activating hot-spot mutations in either 115 
BRAF or NRAS (e.g., BRAFV600, NRASG12 or NRASQ61)2, we examined the nf1/pten-mutant 116 
zebrafish melanomas for spontaneous mutations at equivalent sites in the zebrafish orthologues 117 
(Supplementary Figure S4). Sequencing of eight tumors revealed only wild-type alleles of these 118 
two genes in each tumor (Supplementary Figure S5). Hence, similar to the NF1-mutant class of 119 
human cutaneous melanomas2, the loss of nf1 is sufficient to provide RAS pathway activation, 120 




nf1/pten-mutant melanomas exhibit aberrant activation of the RAS and PI3K pathways and 123 
are highly proliferative. 124 
 Since NF1 and PTEN are well-established negative regulators of RAS and PI3K 125 
signaling7,22, respectively, we postulated that the nf1/pten-mutant melanomas would exhibit 126 
activation of effector pathways downstream of RAS and PI3K. Indeed, we detected high levels of 127 
phosphorylated ERK (pERK), phosphorylated AKT (pAKT) and phosphorylated S6 ribosomal 128 
protein (pS6, an mTOR downstream effector) by immunohistochemistry (IHC) in the nf1/pten-129 
mutant melanomas (Figure 1f), indicating hyperactivation of both RAS and PI3K pathways.  130 
Because these pathways drive proliferation, we next analyzed the proliferative capacity of 131 
nf1/pten-mutant melanomas, observing high levels of expression of proliferating cell nuclear 132 
antigen (PCNA) in 45% of tumor cell nuclei but not the adjacent normal tissue (Figure 1f), 133 
indicating a high tumor proliferative rate.  Apoptotic cells were not observed in these melanomas, 134 
as indicated by the lack of detectable cleaved caspase-3 (Figure 1f).  Hence, combined activation 135 
of the RAS and PI3K pathways, a high proliferative rate and the lack of apoptosis likely account 136 
for the rapid onset and high growth rate of nf1/pten-mutant melanomas.  137 
 138 
nf1/pten-mutant melanomas can be serially transplanted into immunodeficient recipients.  139 
 To assess the transplantation potential of our melanoma model, we isolated nf1/pten-140 
mutant melanoma cells and transplanted them intraperitoneally into the optically clear 141 
immunodeficient rag2E450fs(casper) zebrafish23 (designated “rag2-/-”). Robust engraftment was 142 
observed at the site of injection. All recipient fish demonstrated rapidly growing melanotic tumor 143 
masses within 2 weeks (Figure 1g).  Because of the invasive properties of the primary nf1/pten-144 
mutant melanomas (Figure 1), we also tested the feasibility of their intramuscular transplantation 145 
into rag2-/- zebrafish, where the tumor cells not only expanded within muscle, but also invaded 146 
neighboring tissues such as the ventral fin (Supplementary Figure S6). By contrast, non-147 
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transformed melanocytes (derived from normal pigmented melanocytes within the skin stripes) 148 
from nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-;p53M214K/M214K zebrafish failed to engraft in rag2-/- zebrafish.  149 
Furthermore, although the melanomas arising from the Tg(mitf:BRAFV600E);p53M214K/M214K 150 
zebrafish24 can be serially transplanted into rag2-/- zebrafish, their post-transplantation growth 151 
rates were much slower, highlighting the extraordinarily high growth rate in vivo of the nf1/pten-152 
mutant melanomas.    153 
 154 
MEK and PI3K inhibitors lack efficacy against nf1/pten-mutant melanomas in vivo. 155 
 Human NF1-mutant melanomas have the worst outcome among all metastatic 156 
melanomas8, and PTEN-mutant melanomas are known to be resistant to T-cell mediated 157 
immunotherapy such as the immune checkpoint inhibitor25.  Thus, there is a clear need for 158 
effective small molecule inhibitors to overcome the aggressive growth properties of NF1/PTEN-159 
mutant melanoma.  Because targeting the RAS-MEK-ERK and PI3K-PTEN-AKT-mTOR 160 
signaling pathways might logically affect the growth of nf1/pten-mutant melanomas, we first 161 
transplanted these melanoma cells into 3-week-old rag2-/- zebrafish and treated the recipients with 162 
MEK (trametinib or cobimetinb) or pan-PI3K (buparlisib or apitolisib) inhibitors. The nf1/pten-163 
mutant melanoma cells grew rapidly in DMSO-treated recipients and progressed from an 164 
inoculum of 500 cells to readily detectable pigmented tumors at 4-8 days post-transplantation 165 
(Figure 2a).  Single-agent treatment with either MEK or PI3K inhibitors from days 2-8 post-166 
transplantation at each of their maximum tolerated dosages (MTDs; Supplementary Figure S7a) 167 
did not affect the growth of tumors (Figures 2b and S7b).  Even when tumor-bearing recipient fish 168 
were treated with a combination of trametinib and buparlisib at their MTDs (Supplementary 169 
Figure S7a), tumor growth was only transiently inhibited during treatment, followed by rapid 170 
regrowth after drug removal, resulting in the lack of improvement in overall survival (Figure 2d).  171 
  172 
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Inhibition of mTOR suppresses the growth of nf1/pten-mutant melanomas in vivo. 173 
 To broaden the coverage of candidate pathway inhibitors, we next tested a panel of 174 
antitumor drugs targeting the RAS-MEK-ERK and receptor tyrosine kinase-PI3K-AKT-mTOR 175 
pathways in our nf1/pten-mutant melanoma model by assessing tumor cell growth and overall 176 
survival of recipient rag2-/- fish after 6 days of treatment (Figures 2, S8 and S9).  Among the 14 177 
tested drugs, each at their MTD, only the rapamycin family of mTOR inhibitors (rapalogs) 178 
showed selective activity against nf1/pten-mutant melanoma in vivo as single agents. 179 
Interestingly, four different mTOR kinase inhibitors did not show activity against nf1/pten-mutant 180 
melanomas at their MTD (Supplementary Figure S9).  During the 6-day treatment course, 181 
sirolimus (rapamycin) clearly suppressed the appearance of detectable tumors, and its inhibition 182 
of tumor growth persisted for 1 to 2 weeks post-treatment, in marked contrast to the rapid tumor 183 
regrowth in fish treated with MEK and PI3K inhibitors (Figures 2c, 2e, 3 and S10). We also 184 
treated nf1/pten-mutant melanomas with everolimus and temsirolimus, two FDA-approved 185 
analogs of sirolimus. The three rapalogs showed similar abilities to durably inhibit melanoma cell 186 
growth (Figures 2c and e), which uniformly translated to improved overall survival, indicating 187 
that rapalogs may provide a useful treatment option for these melanomas in vivo.   188 
 Primary nf1/pten-mutant tumors are invariably melanotic, but after serial transplantation, 189 
the tumor cells often become amelanotic26.  In order to track the melanoma cells using EGFP 190 
instead of melanin, we bred the sox10:EGFP fluorescent zebrafish line into our nf1/pten-mutant 191 
line to aid in visualization of the transplanted melanoma cells, as they expressed high levels of the 192 
neural crest progenitor marker sox10 (Supplementary Figure S11)24.  When transplanted into 3-193 
week-old rag2-/- zebrafish and treated for 6 days with multiple different inhibitors, the EGFP-194 
expressing amelanotic cells responded poorly to single-agent treatment with either trametinib or 195 
buparlisib, had only temporary responses to the trametinib-buparlisib combination, but showed 196 
more durable responses to sirolimus and temsirolimus (Supplementary Figure S12). Thus, the 197 
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amelanotic melanoma cells appear to respond in a similar fashion to the melanotic melanoma 198 
cells, reinforcing the dependence of both subtypes of melanoma on mTOR signaling for 199 
malignant cell growth in vivo.  200 
 201 
Cell growth in nf1/pten-mutant melanomas depends on mTOR signaling.  202 
 The RAS-MEK-MAPK and PI3K-AKT-mTOR pathways negatively regulate each other, 203 
such that a drug-induced blockade of one pathway results in increased activity of the other27,28. To 204 
test whether these drugs act on the expected pathways in inhibitor-treated nf1/pten-mutant 205 
melanomas, we analyzed treated tumors by IHC, observing that treatment with the MEK inhibitor 206 
trametinib leads to a reduction in pERK levels (Figures 4a and b), as expected; while levels of 207 
pAKT and pS6 are increased (Figures 4a, c and d), reflecting the loss of RAS-MEK-MAPK-208 
mediated cross-inhibition of PI3K-AKT-mTOR signaling28. Similarly, treatment with the PI3K 209 
inhibitor buparlisib led to a reduction in pAKT and pS6 levels, with loss of RAS-MEK-MAPK-210 
mediated cross-inhibition, resulting in increased pERK levels (Figures 4a-d).  This concomitant 211 
upregulation of an alternative pathway explains why neither buparlisib nor trametinib alone 212 
inhibited tumor-cell proliferation (Figures 4a and e). The trametinib-buparlisib combination 213 
readily inhibited both the RAS and PI3K pathways, leading to a significant, though modest, 214 
decrease in tumor-cell proliferation (Figure 4). Thus, these two pathways appear to function 215 
redundantly in driving the proliferation of nf1/pten-mutant melanomas.  Interestingly, 2 days of 216 
sirolimus treatment resulted in undetectable levels of pS6 staining (Figures 4a and d), reflecting 217 
mTOR inhibition with transient increase and then sustained loss of pERK levels (Figures 4a, 4b 218 
and 5) and suppression of proliferation (Figure 4).  Thus, the sustained compensatory 219 
upregulation of the ERK pathway induced by buparlisib was not evident when mTOR-mediated 220 
phosphorylation was specifically inhibited by sirolimus. 221 
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To assess the durability of pathway suppression by inhibitor treatment, we treated nf1/pten-222 
mutant-melanoma recipients with the inhibitors for 6 days, then analyzed the tumors after 4 days 223 
in the absence of the drugs. Sirolimus led to sustained reductions in pERK, pAKT, pS6, and 224 
PCNA levels at 4 days post-treatment (Figures 5a-c), as part of a cytoprotective autophagy stress 225 
response (Figure 6a). By contrast, the initial signaling and antiproliferative effects of the 226 
trametinib-buparlisib combination (Figure 4) were short-lived, as 4 days after drug removal, the 227 
pERK, pAKT, pS6 and PCNA levels were returning to normal (Figure 5). Similar to sirolimus, 228 
temsirolimus also induced durable inhibition of pS6 and sustained suppression of pERK, pAKT 229 
and tumor proliferation (Supplementary Figure S13).  Thus, in contrast to combined inhibition of 230 
PI3K and MEK, mTOR inhibition alone leads to the sustained suppression of RAS and PI3K 231 
pathways and tumor cell growth in transplanted melanomas.   232 
 233 
Co-inhibition of BCL2 and MCL1 synergizes with sirolimus to cause apoptotic cell death 234 
nf1/pten-mutant melanomas in vivo 235 
It is important to emphasize that while either sirolimus or temsirolimus can induce prolonged 236 
proliferative arrest based on the absence of PCNA staining, we did not detect cleaved caspase 3 in 237 
treated tumor cells (Figures 4a, 5a and S13), indicating that neither agent is cytotoxic as a single 238 
agent. To query further the proliferative arrest induced by these rapalogs, we studied the 239 
autophagy marker LC3 by IHC. This analysis revealed autophagy not only of the tumor cells by 240 
LC3 staining, but also striking levels of autophagy in the brain and liver of the sirolimus-treated 241 
animals (Figure 6a).  The absence of a cytotoxic effect and initiation of autophagy as a cell 242 
survival mechanism would likely limit the therapeutic potential of rapalogs in nf1/pten-mutant 243 
melanomas. Thus, we analyzed a panel of antitumor drugs to identify those with the potential to 244 
synergize with sirolimus by inducing apoptosis, thus converting “cytostatic autophagy” to 245 
“cytotoxic autophagy”29.  This evaluation included MEK inhibitors trametinib and cobimetinib, 246 
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the PI3K inhibitors buparlisib and apitolisib, the pan-RAF inhibitor sorafenib, the PARP inhibitor 247 
olaparib, the autophagy inhibitor chloroquine, and inhibitors of the BCL2 family of pro-survival 248 
proteins including sabutoclax, obatoclax, venetoclax and S63845 (MTD determination see 249 
Supplementary Figure S14).   250 
As shown in Supplementary Figure S15, none of the drugs delayed tumor progression when 251 
given alone to 3-week-old fish bearing nf1/pten-mutant melanomas, and only sirolimus in 252 
combination with venetoclax showed overall survival benefit compared to sirolimus alone.  In 253 
particular, the autophagy inhibitor chloroquine markedly delayed tumor progression when 254 
combined with sirolimus, presumably by blocking the ability of the autophagosomes to fuse with 255 
lysosomes, thus preventing both tumor and normal cells from accessing the nutrients sequestered 256 
in the autophagosome30-32.  However, its use with sirolimus caused massive post-treatment death 257 
of the recipient fish as early as 4 days after drug administration, presumably due to autophagy of 258 
normal tissues such as liver (Figures 6 and S15).  Thus, we sought to identify drugs that would 259 
modify the autophagy response not directly as in the case of chloroquine but selectively by 260 
promoting apoptosis.    261 
Pro-survival members of the BCL2 family of proteins are required for the survival of cells 262 
undergoing autophagy33, with tumor cells typically showing greater dependence on these pro-263 
survival effects because of their higher-than-normal expression of BH3-only initiators of 264 
apoptosis, leading to an increased propensity to undergo apoptosis through a mechanism called 265 
“apoptotic priming”34.  Thus, since pro-survival BCL2 family proteins are essential in the high-266 
stress environment induced by sirolimus, their inhibition would be expected to induce tumor cells 267 
to undergo  apoptosis before normal cells35-38.  Therefore, inhibitors of pro-survival BCL2 family 268 
proteins should have a therapeutic index based on synergy with the effects of sirolimus in targeted 269 
therapy for “primed” NF1/PTEN-mutant tumor cells, while sparing normal tissues.   270 
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To test this hypothesis, we focused on two inhibitors, venetoclax (inhibiting BCL2)39 and 271 
S63845 (inhibiting MCL1)40.  Interestingly, although venetoclax alone had no effect on tumor 272 
growth at a dose of 7.5 μM, its combination with 10 μM sirolimus significantly delayed tumor 273 
progression (Figures 6b and c). Similarly, S63845 alone did not affect tumor growth at a dose of 5 274 
μM, but in combination with 10 μM sirolimus, it augmented the growth suppressive effects of 275 
sirolimus (Figures 6d and e).   276 
It is known that each member of the pro-survival BCL2 family proteins, including BCL2 and 277 
MCL1, can bind and sequester BH3-only proteins independently and thereby prevent these BH3-278 
only proteins from inducing apoptosis by activating BAX and BAK39.  We previously discovered 279 
in vivo synergistic anti-leukemia activity of venetoclax and S63845, as each drug causes marked 280 
compensatory upregulation of MCL1 and BCL2 protein levels when used as single agent in 281 
zebrafish41.  Hence, we reasoned that co-inhibition of BCL2 and MCL1 in nf1/pten-mutant 282 
melanoma cells might produce an even greater synergistic antitumor effect than observed with 283 
either inhibitor given individually with sirolimus. Indeed, when we combined 7.5 μM venetoclax 284 
and 2.5 μM S63845 with 10 μM sirolimus, we observed greatly enhanced growth suppression of 285 
nf1/pten-mutant melanoma cells (Figures 6f and g).  To determine the basis for this boosted 286 
effect, we analyzed the contributions of these three agents to tumor cell proliferation and 287 
apoptosis.  7.5 μM venetoclax and 2.5 μM S63845 had no effect on proliferation or apoptosis, 288 
while 10 μM sirolimus significantly inhibited proliferation but failed to induce apoptosis (Figures 289 
6h and i). In combination, however, the three drugs effectively inhibited proliferation, and 290 
dramatically increased levels of apoptosis (Figures 6h and i).  Importantly, the fish tolerated this 291 
drug combination without noticeable toxicity.  Thus, our results indicate that tumor cells 292 
sensitized by sirolimus become more dependent than normal cells on BCL2 and MCL1 for 293 
sustained survival, thus increasing their susceptibility to apoptosis in the absence of these key pro-294 




Co-inhibition of BCL2 and MCL1 synergizes with sirolimus to induce apoptosis in human 297 
NF1/PTEN-deficient melanoma cells 298 
To validate the efficacy of our three-drug combination, we turned to studies using human 299 
NF1/PTEN-deficient melanoma cells.  For this purpose, we first evaluated the expression level of 300 
neurofibromin and PTEN in a panel of human melanoma cell lines and identified one cell line, 301 
WM-3246, that lacked detectable expression of either neurofibromin or PTEN (Figure 7a).  Then, 302 
using WM-3246 cells, we tested the effects of sirolimus, venetoclax and S63845 on the viability 303 
of NF1/PTEN-deficient melanoma cells.  As a single agent, sirolimus induced only modest levels 304 
of cytostatic growth suppression at concentrations >50 nM (Figures 7b-d).  Venetoclax did not 305 
produce effects on WM-3246 cell growth at concentrations up to 250 nM, whereas S63845 306 
suppressed cell growth in a dose-dependent manner at doses >5 nM (Figures 7b-c).  The greatest 307 
impact on cell growth was evident when sirolimus was tested in combination with venetoclax and 308 
S63845 (Figures 7c-d); synergy was obtained by isobologram analysis over a range of drug 309 
concentrations (Figure 7e), indicating that these cells depend on both BCL2 and MCL1, as well as 310 
on mTOR signaling, for cell growth and survival.  Western blot analysis showed compensatory 311 
upregulation of MCL1 in cells treated with venetoclax (Figure 7f), confirming the molecular basis 312 
for the synergy between S63845 and venetoclax in sirolimus-treated WM-3246 cells.  313 
Furthermore, cleaved caspase 3 in WM-3246 cells treated with the three-drug combination but not 314 
with sirolimus alone (Figure 7g), validating the induction of apoptosis by co-inhibition of BCL2 315 
and MCL1 in sirolimus-sensitized NF1/PTEN-deficient human melanoma cells.   316 
We also tested the three-drug combination identified in our NF1/PTEN-mutant melanoma 317 
model in BRAF-mutant melanomas with PTEN-mutations, because BRAF activation by mutation 318 
is more prevalent than biallelic inactivating mutations of NF1.  Although each of these drugs 319 
demonstrated little or no activity as single agents, the three-drug combination showed significant 320 
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activity against the BRAF-mutant melanoma cells harboring PTEN-mutation (Supplementary 321 
Figure S16).  Furthermore, the venetoclax-S63845 combination potentiated melanoma cell killing 322 
caused by the BRAFV600E inhibitor darafenib in BRAF-mutant melanoma cells (Supplementary 323 
Figure S16), suggesting that co-inhibition of BCL2 and MCL1 as a strategy to enhance the 324 
induction of apoptosis has broad utility as a means to potentiate the activity of targeted therapies 325 




Discussion  328 
Loss-of-function mutations of the NF1 tumor suppressor in human melanoma cells were first 329 
identified by us and others in the early 1990s42,43.  The TCGA program subsequently undertook a 330 
multiplatform characterization of cutaneous melanoma samples at the DNA, RNA and protein 331 
levels, in which NF1-mutant melanoma emerged as an important subtype within a genomic 332 
classification framework2. Although highly useful as a means to identify cooperative molecular 333 
aberrations that might serve as druggable targets or predictive biomarkers, this genomic approach 334 
did not suggest a therapeutic strategy for tumors linked to NF1-loss.  Using a zebrafish 335 
experimental system that models human NF1-mutant melanomas, we show that activation of both 336 
the RAS and PI3K pathways in a background of pten-loss is required to initiate melanomas in 337 
nf1-deficient animals. However, the RAS and PI3K pathways function redundantly in tumor 338 
maintenance, due to compensatory upregulation of either pathway when the other is inhibited 339 
(Figures 4 and 5).  Even simultaneous inhibition of both pathways only transiently inhibited the 340 
growth of nf1/pten-mutant melanomas, such that the overall survival of tumor-bearing fish was 341 
unaffected (Figures 2, S7 and S10). This result contrasts with findings in basal-like breast cancer 342 
cell lines, in which the combination of MEK and PI3K inhibitors produced cytotoxic antitumor 343 
effects44.  344 
Given the superiority of sirolimus in suppressing the growth of transplanted nf1/pten-mutant 345 
melanomas while inducing autophagy in normal tissues, we faced a major challenge: to identify 346 
drugs that could selectively cause apoptosis in sirolimus-sensitized melanoma cells.  Such studies 347 
require an animal model that allows one to simultaneously assess both antitumor effects and 348 
toxicity to normal tissues, a criterion that was readily met by our zebrafish model.  Indeed, while 349 
the antitumor response of nf1/pten-mutant melanomas to the combination of sirolimus and 350 
chloroquine initially appeared promising, the treated fish died due to toxicity to normal tissues 351 
(Supplementary Figure S15), illustrating the importance of analyzing this drug combination in an 352 
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in vivo model system.  By contrast, the combination of sirolimus with inhibitors of the anti-353 
apoptotic proteins BCL2 (venetoclax) and MCL1 (S63845) was both well tolerated by normal 354 
tissues and highly active in inducing apoptosis in tumor cells (Figures 6, 7 and S15).  This 355 
selectivity apparently results from the fact that the malignant cells are “primed” to undergo 356 
apoptosis, while normal cells do not harbor the same levels of upregulation of BH3-only death 357 
proteins and can survive and maintain mitochondrial integrity despite the simultaneous inhibition 358 
of two major pro-survival proteins.  359 
Our results underscore the advantages of using a reliable in vivo preclinical model to analyze 360 
the effects of simultaneously inhibiting multiple pathways with small-molecule drugs.  Given its 361 
greater efficiency and lower costs compared to murine models, our zebrafish experimental system 362 
appears ideal for pursuing additional classes of pathway inhibitors in NF1/PTEN-mutant 363 
melanomas, as single agents and in combination, to define their clinical translational potential.   364 
Thus, the three-drug combination of sirolimus, venetoclax and S63845 is well tolerated at 365 
effective dosages in vivo and shows activity against human as well as zebrafish NF1/PTEN-366 
deficient melanoma cells, providing preclinical evidence justifying an early stage clinical trial in 367 
patients with melanomas of this high-risk genomic subtype.  Notably, the three-drug combination 368 
identified in our NF1/PTEN-mutant melanoma model also showed anti-melanoma activity in 369 
BRAF-mutant melanoma cells harboring PTEN-mutation (Supplementary Figure S16).  370 
Furthermore, the venetoclax-S63845 combination potentiated melanoma cell killing caused by the 371 
BRAFV600E inhibitor darafenib in BRAF-mutant melanoma cells (Supplementary Figure S16).  372 
Thus the potentiation of apoptosis induced by co-inhibition of BCL2 and MCL1 is a strategy with 373 
wide applicability to enhance the anti-melanoma activity by targeted therapies in malignant 374 




Materials and Methods 377 
 378 
Zebrafish 379 
Zebrafish experiments and animal husbandry were performed in accordance with Dana-Farber 380 
Cancer Institute IACUC-approved protocol #02-107.   381 
 382 
Melanoma tumor watch  383 
nf1a+/-;nf1b+/-;ptena+/-;ptenb+/-;p53+/M214K mutant zebrafish were incrossed, and offspring were 384 
monitored every week, starting at 3 weeks, for hyperpigmented cell masses indicative of 385 
melanoma tumors.  Once a hyperpigmented cell mass was identified, the individual fish was 386 
separated and carefully monitored weekly for at least 3 weeks for tumor progression.  Only fish 387 
with expanding hyperpigmented cell masses were scored as tumor fish and analyzed further by 388 
H&E staining and immunohistochemical assays. All fish were genotyped for nf1a, nf1b, ptena, 389 
ptenb and p53 at the age of 6 weeks.  The exact sample size (n) for each experimental group is 390 
indicated in the figures. 391 
 392 
Tumor cell transplantation 393 
rag2E450fs(casper) (rag2-/-) zebrafish were anaesthetized with 0.003% tricaine (Sigma-Aldrich, St. 394 
Louis, MO) and positioned on a 10-cm Petri dish coated with 1% agarose.  Primary and serially-395 
passaged tumors derived from nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-;p53M214K /M214K and nf1a+/-;nf1b-/-396 
;ptena+/-;ptenb-/-;p53M214K/M214K;Tg(sox10:EGFP) zebrafish lines were excised from tumor-397 
bearing fish and mechanically dissociated with a razor blade in 0.9X PBS + 5% FBS (Life 398 
Technologies, Carlsbad, CA) at room temperature.  Collected cell suspension was filtered through 399 
a 40-μm cell strainer (Falcon, Corning, NY) and resuspended in 0.9X PBS + 5% FBS. For the 400 
intraperitoneal and intramuscular transplantation into 3- to 4-month-old adult rag2-/- fish, a 401 
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26s/2”/2 Hamilton 80300 syringe (Hamilton, Reno, NV) was used23.  For the intraperitoneal 402 
transplantation into 3-week-old juvenile rag2-/- fish, cell suspensions were loaded into borosilicate 403 
glass capillary needles (1 mm o.d. × 0.78 mm i.d.; Harvard Apparatus, Holliston, MA), and the 404 
injections were performed with a Pneumatic Picopump and a manipulator (WPI, Sarasota, FL) 45.  405 
 406 
Cell culture 407 
Melanoma cell lines Mewo, WM-3246, WM-3622, WM-3629, WM-3670 and WM-3918 were 408 
purchased from Rockland (Rockland Immunochemicals Inc, Limerick, PA), and maintained in 409 
Dulbecco's modified Eagle's medium supplemented with 10% FBS, L-glutamine, and 410 
penicillin/streptomycin. Melanoma cell lines COLO829 and C32 were purchased from ATCC 411 
(ATCC, Manassas, VA) and maintained according to the provided Culture Methods. HEK-293T 412 
cells were purchased from ATCC, and maintained in Dulbecco's modified Eagle's medium 413 
supplemented with 10% FBS, L-glutamine, and penicillin/streptomycin. Jurkart cells were 414 
maintained in RPMI-1640 medium supplemented with 10% FBS, L-glutamine, and 415 
penicillin/streptomycin.  The identity of cell lines used in this study was verified by short tandem 416 
repeat analysis using the PowerPlex 1.2 system (Promega).  The cell lines were tested for 417 
mycoplasma contamination using MycoAlert Mycoplasma Detection Kits (Lonza).  418 
 419 
Statistical analysis 420 
Statistical analysis was performed with Prism 5 software (GraphPad). Kaplan-Meier methods and 421 
the log-rank test were applied to assess the rate of tumor growth in Figure 1 and S1, and tumor 422 
progression in Figures 2, 6, S7, S8, S9, S10 and S15. The quantitative data in Figures 3, 4, 5 and 423 
S12 are reported as median values. A Mann-Whitney test with confidence intervals of 95% was 424 
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Figures and Tables 565 
 566 
Figure 1: nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-;p53M214K/M214K zebrafish spontaneously develop 567 
melanomas with rapid growth. 568 
(a) Representative 16-week-old nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-;p53M214K/M214K zebrafish with one 569 
spontaneous melanoma (indicated by arrow). (b) Hematoxylin and eosin (H&E) staining of the 570 
melanoma tumor shown in panel a (5x magnification, scale bar = 200 μm). (c) Melanoma tumor 571 
cells from the black box in panel B, magnified 100X. (d) Melanoma tumor cells that have invaded 572 
into the dorsal muscle from the white box in panel B, magnified 100X. (e) Cumulative frequency 573 
of spontaneous melanomas arising in zebrafish with the indicated genotypes (generated by the 574 
inbreeding of the nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-;p53M214K/M214K line, p < 0.0001, log-rank test).  (f) 575 
Immunohistochemical analysis of melanoma tumor sections using antibodies to detect 576 
phosphorylated ERK1/2 (pERK), phosphorylated AKT (pAKT), phosphorylated S6 (pS6), 577 
proliferating cell nuclear antigen (PCNA) and cleaved caspase 3 (CC3) (63x magnification, scale 578 
bar = 20μm). The percentage of PCNA+ cells was determined by manually counting positive and 579 
negative melanoma cells in one representative high-power field (150 to 200 cells per field) within 580 
three independent tumor samples. (g) Pigmented nf1/pten-mutant melanoma cells were 581 
transplanted intraperitoneally into adult rag2-/- Casper zebrafish. The implanted melanoma cells 582 
(left panel, arrow) grew rapidly into secondary tumors (within 2 weeks; right panel).  583 
 584 
Figure 2: mTOR inhibitors achieve a durable antitumor effect in nf1/pten-mutant 585 
melanoma.   586 
(a) Schematic of the melanoma tumor transplantation assay.  (b, c) Transplanted nf1/pten-mutant 587 
melanoma tumor cells were monitored daily in 3-week-old rag2-/- recipient zebrafish treated with 588 
DMSO (CTR; n=12), 80 nM trametinib (n=11), 2 μM buparlisib (n=11), or the combination of 80 589 
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nM trametinib and 2 μM buparlisib (n=12) for 6 days.  Kaplan-Meier curves for progression-free 590 
survival (PFS, panel b) and overall survival (OS, panel c) are shown. Statistical analyses were 591 
performed by log-rank test, comparing drug-treated with DMSO-treated zebrafish. (d, e) 592 
Transplanted nf1/pten-mutant melanoma tumor cells were monitored daily in 3-week-old rag2-/- 593 
recipient zebrafish treated with DMSO (CTR; n=12, same values as in panels b, c), 20 μM 594 
sirolimus (n=12), 20 μM everolimus (n=11) or 40 μM temsirolimus (n=11) for 6 days.  Kaplan-595 
Meier curves are shown, with statistical analyses performed as in panels B, C. For all experiments 596 
involving drug treatments, drugs were replenished every 2 days during the 6-day course of 597 
treatment (black arrows).  598 
 599 
Figure 3: Sirolimus, but not trametinib or buparlisib, prevents rapid relapse of nf1/pten-600 
mutant melanoma following treatment.  Three-week-old rag2-/- zebrafish transplanted with 601 
pigmented nf1/pten-mutant melanoma cells were treated for 6 days with DMSO, 80 nM 602 
trametinib, 2 μM buparlisib, the combination of 80 nM trametinib and 2 μM buparlisib, or 20 μM 603 
sirolimus. (a, c, e, g, and i) Representative zebrafish at the end of the 6-day drug treatment. (b, d, 604 
f, h, and j) Representative zebrafish at 4 days following the end of drug treatment. (k) 605 
Quantification of melanotic nf1/pten-mutant tumor-cell area at the end of the 6-day course of drug 606 
treatment (left), and 4 days later (right). ns p>0.05, *p<0.05, **p<0.01, ***p<0.001 by two-tailed, 607 
unpaired t-test. Scale bar = 1mm. 608 
 609 
Figure 4: Sirolimus strongly inhibits proliferation in nf1/pten-mutant melanomas. (a) 610 
Representative tissue sections from a transplanted nf1/pten-mutant melanoma tumor after 2 days 611 
of treatment with DMSO (CTR), 80 nM trametinib, 2 μM buparlisib, the combination of 80 nM 612 
trametinib and 2 μM buparlisib, or 20 μM sirolimus.  Sections were immunostained using 613 
antibodies to detect pERK, pAKT, pS6, PCNA, and cleaved caspase-3 (CC3).  pERK-, pAKT- 614 
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and pS6-positive tumor areas, as well as PCNA-positive nuclei, are quantified post-treatment in 615 
panels b-e. “T+B” refers to trametinib plus buparlisib. ns p>0.05, * p<0.05, ** p<0.01 by Mann-616 
Whitney test. Scale bar = 20 μm.   617 
 618 
Figure 5: Sirolimus induces a durable cytostatic effect in nf1/pten-mutant melanomas. (a) 619 
Representative tissue sections from a transplanted nf1/pten-mutant melanoma tumor at 4 days 620 
after a 6-day drug treatment with DMSO (CTR), 80 nM trametinib, 2 μM buparlisib, the 621 
combination of 80 nM trametinib and 2 μM buparlisib, or 20 μM sirolimus.  Sections were 622 
immunostained using antibodies to detect pERK, pAKT, pS6, PCNA, and CC3.  pERK-, pAKT- 623 
and pS6-positive tumor areas, as well as PCNA-positive nuclei, are quantified in panels b-e. 624 
“T+B” refers to trametinib plus buparlisib. ns p>0.05, * p<0.05, ** p<0.01 by Mann-Whitney 625 
test. Scale bar = 20 μm.   626 
 627 
Figure 6:  Sirolimus synergizes with venetoclax and S63845 to suppress nf1/pten-mutant 628 
melanoma tumor growth and extend the survival of tumor-bearing zebrafish.  (a) 629 
Representative sagittal tissue sections from a transplanted nf1/pten-mutant melanoma tumor 630 
treated for 2 days with the indicated drugs. Sections were immunostained with antibodies to 631 
detect LC3A/B. Left panels: E=eye, B=brain, G=gut, K=kidney, L=liver, S=swim bladder, 632 
T=tumor. Right panels: 63X magnification of tumor cells from the small black boxes in left 633 
panels. (b-g) Transplanted nf1/pten-mutant melanoma tumor cells were monitored daily in 3-634 
week-old rag2-/- recipient zebrafish treated with DMSO (CTR), venetoclax, S63845, sirolimus, or 635 
the drug combinations (n=11 or 12 for each curve; doses as indicated). Kaplan-Meier curves for 636 
PFS (panels b, d and f) and OS (panels c, e and g) were compared using a log-rank test. Drugs 637 
were refreshed every 2 days during the 6-day course of treatment, as indicated by black arrows. 638 
(h) Representative tissue sections from transplanted nf1/pten-mutant melanoma tumors treated for 639 
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2 days with DMSO (CTR), 7.5 μM venetoclax and 2.5 μM S63845, 10 μM sirolimus, and the 640 
three-drug combination. Sections were immunostained using antibodies to detect PCNA and CC3 641 
and quantified in (i). ns p>0.05, ***p<0.0001 by Mann-Whitney test. Scale bars = 20 μm. 642 
 643 
Figure 7: Venetoclax and S63845 synergize with sirolimus to induce apoptosis in human 644 
NF1/PTEN-deficient melanoma cells. (a) Western blots for NF1 and PTEN in a panel of human 645 
melanoma cell lines.  HEK293 and Jurkart cells were included as positive and negative controls.  646 
The levels of total ERK1/2 expression serve as the loading control. (b) Relative cell viability of 647 
WM-3246 cells (Cell Titer Glo assay) upon treatment with sirolimus, venetoclax or S63845 for 6 648 
days. Mean ± s.d. values. (c) Relative cell viability of WM-3246 cells (Cell Titer Glo assay) upon 649 
treatment with the combination of sirolimus, venetoclax and S63845 for 6 days. Mean ± s.d. 650 
values.  (d) WM-3246 cell growth kinetics after treatment with the combination of sirolimus, 651 
venetoclax and S63845 (for doses see panel c). Mean ± s.d. values.  (e) Synergistic effects of 652 
venetoclax and S63845 on suppression of sirolimus-sensitized WM-3246 cells were analyzed by 653 
isobologram analysis. (f) Western blots for BCL2, BCLXL and MCL1 in WM-3246 cells treated 654 
with venetoclax or S63845 for 24 hours. (g) Western blots for cleaved caspase-3 in WM-3246 655 
cells treated with the combination of sirolimus, venetoclax and S63845.  656 
 657 
Supplementary Materials 658 
 659 
Supplementary Figure 1: Cumulative frequency of tumor development in fish with the indicated 660 
genotypes. Malignant peripheral nerve sheath tumors (MPNSTs) comprise the majority of tumors; 661 
high grade gliomas are indicated by red arrows with the single black arrow indicating a 662 




Supplementary Figure 2: Sections from a spontaneous melanoma from a 20-week-old nf1a+/-665 
;nf1b-/-;ptena+/-;ptenb-/-;p53+/M214K zebrafish were stained for H&E, pERK, pAKT, pS6, and 666 
PCNA (63x magnification, Scale bar = 20 μm). 667 
 668 
Supplementary Figure 3: DNA PCR of nf1a and ptena genes were performed from two pairs of 669 
independent melanoma tumors (T1 and T2) and the corresponding adjacent non-tumor muscle 670 
tissue (A1 and A2).  The PCR products were then cut with restriction enzymes that only digests 671 
the wild-type allele but not the mutant allele (DdeI for nf1a and RsaI for ptena).  Electrophoresis 672 
was performed using 3% MetaPhor agarose.  The results showed that the wild-type allele of each 673 
gene is retained by the tumor cells.   674 
 675 
Supplementary Figure 4: Amino acid sequence alignment of human and zebrafish BRAF (a) and 676 
NRAS (b).  The sites of BRAF codons V600, and NRAS codons G12 and Q61, are highlighted by 677 
red boxes.  678 
 679 
Supplementary Figure 5: Representative sequencing chromatograms of zebrafish codons, shown 680 
are braf codon V610, and nras codons G12 and Q61 from genomic DNA isolated from a 681 
melanoma tumor (bottom) and matched tumor-free tail fin (top). 682 
 683 
Supplementary Figure 6: Rapid growth of nf1/pten-mutant melanoma following intramuscular 684 
engraftment into adult rag2-/- Casper zebrafish.  The implanted melanoma cells (a, indicated by 685 
the arrow) grew aggressively into secondary tumors within 2 weeks (b). 686 
 687 
Supplementary Figure 7: (a) Dose matrices were generated to assess the tolerability of 3-week-688 
old zebrafish to MEK and PI3K inhibitors. Each matrix sampled mixtures of 2 serially diluted 689 
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single-agent concentrations. Three 3-week-old wild-type zebrafish were independently treated 690 
with each mixture for 7 days, with drug refreshments at days 2 and 4.  The numbers of fish 691 
surviving the treatment was measured at the end of day 7.  (b) Transplanted nf1/pten-mutant 692 
melanoma tumor cells were monitored daily in 3-week-old rag2-/- recipient zebrafish treated with 693 
DMSO (CTR; n=12), 1 μM cobimetinib (n=11) and 5 μM apitolisib (n=11) for 20 days. Kaplan-694 
Meier curves for PFS (left) and OS (right) were compared using a log-rank test.  695 
 696 
Supplementary Figure 8: Transplanted nf1/pten-mutant melanoma cells were monitored daily in 697 
3-week-old rag2-/- recipient zebrafish treated with DMSO (CTR) or selected drugs (n=11 or 12 698 
for each curve). Kaplan-Meier curves for progression-free (left) or overall (right) survival were 699 
compared with a log-rank test. 700 
 701 
Supplementary Figure 9: Transplanted nf1/pten-mutant melanoma cells were monitored daily in 702 
3-week-old rag2-/- recipient zebrafish treated with DMSO (CTR) or selected mTOR inhibitors 703 
(n=11 or 12 for each curve). Kaplan-Meier curves for progression-free (left) or overall (right) 704 
survival were compared with a log-rank test. 705 
 706 
Supplementary Figure 10: Transplanted nf1/pten-mutant melanoma tumor cells were monitored 707 
daily in 3-week-old rag2-/- recipient zebrafish treated with DMSO (CTR; n=12), 80 nM trametinib 708 
(n=11), 2 μM buparlisib (n=12), the combination of 80 nM trametinib and 2 μM buparlisib 709 
(n=11), or 20 μM sirolimus (n=12) for 15 days.  Kaplan-Meier curves for progression-free (left) 710 





Supplementary Figure 11: Representative tissue section from a transplanted melanoma tumor 714 
derived from nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-;p53M214K/M214K;Tg(sox10:EGFP) zebrafish 715 
immunostained with an antibody to GFP.  Within the amelanotic tumor mass, a GFP-expressing, 716 
melanin-positive melanoma cell is indicated by the arrow. Scale bar = 20μm. 717 
 718 
Supplementary Figure 12: mTOR inhibitors sirolimus and temsirolimus produce a durable 719 
antitumor effect on amelanotic nf1/pten-mutant melanoma cells.  (a) EGFP-positive 720 
amelanotic melanoma cells were isolated from nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-721 
;p53M214K/M214K;sox10:EGFP zebrafish and injected intraperitoneally into 3-week-old rag2-/- 722 
zebrafish.  Starting at 2 days post-transplantation, the recipient fish were treated with DMSO 723 
(CTR), 80 nM trametinib, 2 μM buparlisib, the combination of 80 nM trametinib and 2 μM 724 
buparlisib, 20 μM sirolimus, or 40 μM temsirolimus for 6 days. EGFP-expressing tumors were 725 
photographed at 4 days post-treatment.  The EGFP-expressing area appears as green while the 726 
autofluorescence in the gastrointestinal tract appears as yellow. Scale bar = 1 mm.  (b) 727 
Quantification of the area of EGFP tumor fluorescence immediately after the 6-day course of drug 728 
treatment (left) and 4 days later (right). “T+B” refers to trametinib plus buparlisib. ns p>0.05, 729 
*p<0.05, **p<0.01, ***p<0.001 by two-tailed unpaired t-test.   730 
 731 
Supplementary Figure 13:  Representative tissue sections from a transplanted nf1/pten-mutant 732 
melanoma at 4 days after a 6-day drug treatment with DMSO (CTR) and 40 μM temsirolimus. 733 
Sections were immunostained with antibodies to detect pERK, pAKT, pS6, PCNA and CC3. 734 
 735 
Supplementary Figure 14:  Dose matrices were generated to assess the tolerability of 3-week-736 
old zebrafish to sirolimus combined with the indicated drugs. Each matrix sampled mixtures of 2 737 
serially diluted single-agent concentrations.  Three 3-week old wild-type zebrafish were 738 
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independently treated with each mixture for 7 days, with drug replenishment at days 2 and 4. The 739 
numbers of fish surviving the treatment was measured at the end of day 7. 740 
 741 
Supplementary Figure 15:  Three-week-old rag2-/- recipient zebrafish were transplanted with 742 
nf1/pten-mutant melanoma cells and treated with selected drugs as single agents or in 743 
combination with 5 μM sirolimus (n=11 or 12 for each curve). Kaplan-Meier curves for 744 
progression-free (left) or overall (right) survival were compared with a log-rank test. Drugs were 745 
replenished every 2 days during the 6-day course of treatment (black arrows). 746 
 747 
Supplementary Figure 16:  (a) Venetoclax and S63845 synergize with sirolimus to suppress 748 
human melanoma cells harboring BRAFV600E and PTEN mutations. Relative cell viability of 749 
COLO829 and C32 cells (Cell Titer Glo assay) upon treatment with the combination of sirolimus, 750 
venetoclax and S63845 for 3 days. Mean ± s.d. values.  (b) Venetoclax and S63845 synergize 751 
with dabrafenib to kill BRAF-mutant melanoma cells.  Relative cell viability of C32 cells (Cell 752 
Titer Glo assay) upon treatment with the combination of dabrafenib, venetoclax and S63845 for 3 753 




Supplementary Material and Methods 756 
 757 
DNA extraction, PCR and sequencing 758 
From each nf1a+/-;nf1b-/-;ptena+/-;ptenb-/-;p53 M214K/M214K fish, the melanoma tumor and the tumor-759 
free tail fin were excised, and genomic DNA was extracted with 30 μL QuickExtract DNA 760 
Extraction Solution (Epicentre, Madison, WI) according to the manufacturer’s instructions.  PCR 761 
reactions were performed in a 25 μL volume consisting of 4 μL genomic DNA, 1.4 μL 2.5 mM 762 
dNTP (Invitrogen, Carlsbad, CA), 0.16 μL SuperTaq enzyme (NEB, New England Biolabs, 763 
Ipswich, MA), 2.5 μL 10x SuperTaq buffer (NEB) and 1.4 μL 10 μM primer mix. Cycling 764 
parameters were 1) 94°C for 2 min, 2) 40 cycles at 94°C for 30 sec, annealing (temperature 765 
depends on primer sets, see below) for 30 sec, and elongation at 72°C for 30 sec, and 3) final 766 
elongation for 5 min at 72°C.  PCR primer sequences and annealing temperatures were as follow: 767 
nf1a forward, 5’-GGTGTGTATGTAAATGGGCTCAATG-3’ and reverse 5’-768 
TACAGTTTCCATAAAACCTGACATTTC-3’ (62°C); ptena forward, 5’- 769 
TTGCCATGGGCTTTCCAGCCGTA-3’ and reverse 5’-770 
CCACGTTGACTTACCGGACAACGTCA-3’ (53°C); brafV610 forward, 5’-771 
ATTAGCCGTAACATCACTTCTCTAG-3’ and reverse 5’-772 
ATGTAAGATGTGTTCCTTCACTCAC-3’ (53°C); nrasG12 forward, 5’- 773 
GCTTACTCTCTGTCTTTAATTAC-3’ and reverse 5’- AAGTATAGTAAATTTCCTCAT-3’ 774 
(53°C); nrasQ61 forward, 5’-GTGGCAATCTTGTCTTTC-3’ and reverse 5’-775 
CTGCTCTCAGACCTGTAC-3’ (60°C).  Sequencing of the PCR reaction products were 776 
performed by Genewiz (Cambridge, MA).  777 
 778 
Immunohistochemistry  779 
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Zebrafish were euthanized in tricaine anesthetic, fixed in 4% paraformaldehyde at 4°C for 2 days, 780 
and decalcified with 0.25 M EDTA, pH 8.0, for at least 24 hr.  Paraffin sectioning followed by 781 
H&E staining or IHC was performed at the Dana-Farber/Harvard Cancer Center Research 782 
Pathology Core.  Primary antibodies included phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204, 783 
Cell Signaling #4370; 1:150), phospho-AKT (Ser473, Cell Signaling #4060), phospho-S6 784 
ribosomal protein (Ser240/244, Cell Signaling #4838), PCNA (PC10, EMD Millipore; 1:100), 785 
cleaved caspase-3 (Cell Signaling #9664; 1:100), GFP (Abcam #6556, 1:150), LC3A/B (Cell 786 
Signaling #12741; 1:200), HSP90 (Cell Signaling #4874; 1:100), and HSP70 (Enzo #ADI-SPA-787 
810; 1:25).  Antibody binding was detected with either a diaminobenzidine-peroxidase (DAB) 788 
visualization system (EnVision+, Dako, Carpinteria, CA) or a Bond Polymer Refine Red 789 
Detection Kit (Leica Biosystems, Buffalo Grove, IL). Mayer’s hematoxylin was used for 790 
counterstaining. 791 
 792 
Imaging and quantification 793 
For brightfield DIC images, a Zeiss Axio Imager.Z1 compound microscope equipped with an 794 
AxioCam HRc was used.  For live imaging, zebrafish were anaesthetized using 0.016% tricaine 795 
(Sigma) and mounted in 3% methylcellulose (Sigma).  A Nikon SMZ1500 microscope equipped 796 
with a Nikon digital sight DS-U1 camera was used for capturing both the brightfield and 797 
fluorescent images from live zebrafish.  For melanoma quantification, all animals in the same 798 
experiments were imaged under the same conditions, and the acquired fluorescent images were 799 
quantified using the ImageJ software by measuring the pigment or EGFP fluorescence. The 800 
pigment or fluorescent area was normalized against the surface area of the fish head to control for 801 
varying size of fish. Overlays were created using ImageJ and Adobe Photoshop 7.0.1.   802 
 803 
Drug treatment 804 
33 
 
After 2 days of post-transplantation recovery, the 3-week-old juvenile rag2-/- fish transplanted 805 
with nf1/pten-mutant melanoma cells were randomly separated and treated with trametinib 806 
(Selleck Chemicals, Houston, TX), cobimetinib (Selleck), buparlisib (Selleck), apitolisib 807 
(Selleck), sirolimus (rapamycin, LC Laboratories, Woburn, MA), everolimus (LC Laboratories), 808 
temsirolimus (LC Laboratories), sorafenib (LC laboratories), sabutoclax (Selleck), obatoclax 809 
(Santa Cruz), chloroquine (Sigma), olaparib (Selleck), venetoclax (Chemietek, Indianapolis, IN) 810 
and S63845 (Chemgood, Glen Allen, VA) with refreshment every 2 days.  Sample size was 811 
estimated according to https://www.statstodo.com/SSizSurvival_Pgm.php, that with at least 10 812 
animal per group, we will have 90% power to identify 20% tumor suppression, or 95% power to 813 
identify 50% tumor suppression, testing at the 0.05 one sided level using a log-rank test.  The 814 
drug treatment experiments were all blinded that the drug administration and tumor progression 815 
monitoring were performed by independent investigators.  The treatment conditions were 816 
unblinded after the completion of tumor monitoring.  Each experiment was replicated at least 817 
three times in the laboratory.  818 
 819 
Western blots and antibodies 820 
Whole-cell lysates were prepared in RIPA buffer. Protein concentration was quantified with a 821 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc.).  Equivalent amounts of protein 822 
were diluted in the Laemmli samples buffer (Bio-Rad Laboratories) and separated by SDS-PAGE. 823 
Proteins were transferred to PVDF membranes (Millipore, Billerica, MA) and subjected to 824 
immune blot analysis with each of the specific antibodies for NF1 (Bethyl Laboratories #A300-825 
140A-M; 1:2000 dilution), PTEN (Cell Signaling #9188; 1:1000 dilution), total ERK1/2 (Cell 826 
Signaling #4695; 1:1000 dilution), and cleaved caspase 3 (Cell Signaling #9661; 1:500 dilution).  827 
All primary antibodies were diluted in 5% milk in PBST (0.5% Tween-20 in PBS). 828 
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